New study aims to boost harm reduction for black and latinx drug users

NCT ID NCT05776316

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an 8-week culturally responsive harm reduction program helps Black and Latinx people who use drugs engage more with services and reduce opioid or stimulant use. Researchers will compare the program to standard harm reduction services in 200 participants. The goal is to improve health and reduce drug-related harms in these communities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Integrated Harm Reduction Intervention (IHRI) - an 8-week behavioral program with education and referrals
What this could lead to: If successful, this could show that a culturally tailored program helps Black and Latinx people who use drugs engage more with harm reduction services and reduce their drug use.
What could go wrong: This is a small early-stage study (200 participants) testing a behavioral intervention, so results may not apply broadly. It relies on self-reported drug use, which can be unreliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG USE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Harm Reduction opiate dependence psychiatric disorder substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG USE MENTAL ILLNESS SUBSTANCE ABUSE

Contacts and locations

Locations

NYU Langone Health
NOT_YET_RECRUITING

New York, New York, 10016, United States
Nathan Kline Institute
RECRUITING

Orangeburg, New York, 10962, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.